347850.KQ
D&D Pharmatech
KOE · Healthcare · Biotechnology · KR
KRW 48,500.00
−1.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.8B | 4.3B | 11.4B | 18.7B | 610.6M |
| Cost of Revenue | 5.7B | 5.5B | — | 21.4M | 31.4M |
| Gross Profit | (1.6B) | (1.2B) | 11.4B | 18.7B | 579.2M |
| Operating Expenses | |||||
| R&D Expense | 24.7B | 25.1B | 23.3B | 20.0B | 47.1B |
| SG&A Expense | 4.6B | 2.4B | 2.7B | 2.2B | 2.0B |
| General & Admin Expense | 913.7M | 1.1B | 1.2B | 1.0B | 844.5M |
| Selling & Marketing Expense | 1.1B | 1.3B | 1.4B | 1.2B | 1.2B |
| Other Expenses | 13.9B | 5.3B | 10.5B | 10.0B | 20.1B |
| Total Operating Expenses | 36.1B | 32.8B | 36.5B | 32.2B | 69.3B |
| Cost and Expenses | 40.4B | 38.3B | 36.5B | 32.2B | 69.3B |
| Operating Income (EBIT) | (37.6B) | (34.0B) | (25.0B) | (13.5B) | (68.7B) |
| Non-Operating | |||||
| Interest Income | 2.0B | 861.8M | 1.1B | 570.2M | 729.1M |
| Interest Expense | 3.1B | 470.6M | 614.8M | 1.4B | 3.0B |
| Net Interest Income | (1.1B) | 391.2M | 499.5M | (856.6M) | (2.2B) |
| Other Non-Op Income/Expense | 14.9B | 9.1B | (5.3B) | 18.0B | (94.9B) |
| Non-Operating Income (excl Interest) | (12.5B) | — | 4.7B | (19.4B) | 12.8B |
| EBT (Pre-Tax Income) | (22.7B) | (24.9B) | (30.4B) | 4.5B | (163.5B) |
| Income Tax Expense | (939.7M) | (921.6M) | (873.7M) | 1.1B | (26.5B) |
| Bottom Line | |||||
| Net Income | (21.6B) | (23.6B) | (28.6B) | 3.9B | (136.1B) |
| Earnings from Cont. Ops | (21.8B) | (24.0B) | (29.5B) | 3.4B | (137.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (25.7B) | (33.9B) | (28.6B) | 3.9B | (136.1B) |
| Per Share | |||||
| Basic EPS | (₩504) | (₩547) | (₩706) | ₩105 | (₩4,221) |
| Diluted EPS | (₩589) | (₩772) | (₩706) | ₩105 | (₩3,635) |
| Revenue Per Share | ₩62 | ₩99 | ₩282 | ₩498 | ₩19 |
| Shares | |||||
| Basic Shares Outstanding | 44.1M | 43.5M | 40.6M | 37.5M | 32.2M |
| Diluted Shares Outstanding | 45.1M | 43.5M | 40.6M | 37.5M | 37.4M |
| Profitability Metrics | |||||
| EBITDA | (30.3B) | (28.5B) | (24.2B) | (9.1B) | (54.9B) |
| D&A | 5.7B | 5.5B | 5.5B | 4.4B | 13.7B |
| EBIT | (36.0B) | (34.0B) | (29.7B) | (13.5B) | (68.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026